<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.2 20060430//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-6-278</article-id><article-id pub-id-type="pmid">17150109</article-id><article-id pub-id-type="doi">10.1186/1471-2407-6-278</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A novel mutation in the tyrosine kinase domain of <italic>ERBB2 </italic>in hepatocellular carcinoma</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Bekaii-Saab</surname><given-names>Tanios</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>Tanios.Bekaii-Saab@osumc.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Williams</surname><given-names>Nita</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Nita.Williams@osumc.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Plass</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Christoph.Plass@osumc.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Calero</surname><given-names>Miguel Villalona</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>Miguel.Villalona@osumc.edu</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Eng</surname><given-names>Charis</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>engc@ccf.org</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA</aff><aff id="I2"><label>2</label>Department of Pharmacology, The Ohio State University, Columbus, Ohio, USA</aff><aff id="I3"><label>3</label>Division of Human Genetics, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA</aff><aff id="I4"><label>4</label>Department of Molecular Virology, Immunology and Medical Genetics; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA</aff><aff id="I5"><label>5</label>Genomic Medicine Institute and Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>6</day><month>12</month><year>2006</year></pub-date><volume>6</volume><fpage>278</fpage><lpage>278</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/278"/><history><date date-type="received"><day>24</day><month>8</month><year>2006</year></date><date date-type="accepted"><day>6</day><month>12</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Bekaii-Saab et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Bekaii-Saab et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Bekaii-Saab Tanios Tanios.Bekaii-Saab@osumc.edu </dc:author><dc:title> A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>BMC Cancer 6(1): 278-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2006)6:1&#x0003c;278&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Several studies showed that gain-of-function somatic mutations affecting the catalytic domain of <italic>EGFR </italic>in non-small cell lung carcinomas were associated with response to gefitinib and erlotinib, both <italic>EGFR</italic>-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung carcinomas were shown to have <italic>ERBB2 </italic>mutations in the kinase domain. In our study, we sought to determine if similar respective gain-of-function <italic>EGFR </italic>and <italic>ERBB2 </italic>mutations were present in hepatoma and/or biliary cancers.</p></sec><sec sec-type="methods"><title>Methods</title><p>We extracted genomic DNA from 40 hepatoma (18) and biliary cancers (22) samples, and 44 adenocarcinomas of the lung, this latter as a positive control for mutation detection. We subjected those samples to PCR-based semi-automated double stranded nucleotide sequencing targeting exons 18&#x02013;21 of <italic>EGFR </italic>and <italic>ERBB2</italic>. All samples were tested against matched normal DNA.</p></sec><sec><title>Results</title><p>We found 11% of hepatoma, but no biliary cancers, harbored a novel <italic>ERBB2 </italic>H878Y mutation in the activating domain.</p></sec><sec><title>Conclusion</title><p>These newly described mutations may play a role in predicting response to EGFR-targeted therapy in hepatoma and their role should be explored in prospective studies.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Mutations in the protein-kinase enzyme family, such as the epidermal growth factor receptor (<italic>EGFR</italic>, <italic>ERBB2</italic>), found in human cancers are being investigated as promising targets for the development of novel antitumor therapies.<italic>EGFR </italic>is the first described member of a family of related transmembrane receptor tyrosine kinases. It is comprised of the following four related receptors: <italic>EGFR </italic>itself (<italic>ERBB1 </italic>or HER1), <italic>ERBB2 </italic>(HER2/<italic>neu</italic>), <italic>ERBB3 </italic>(HER3) and <italic>ERBB4 </italic>(HER4). <italic>ERBB </italic>receptors are composed of an extracellular ligand-binding domain, a transmembrane segment, and an intracellular protein tyrosine kinase domain. These receptors trigger downstream signaling pathways that are complex and multilayered. Deregulation of those <italic>ERBB </italic>receptors can lead to malignant transformation. These receptors form either homo- or heterodimeric complexes which provides amplification and diversification [<xref ref-type="bibr" rid="B1">1</xref>]. Heterodimerization of the <italic>ERBB2 </italic>and <italic>EGFR </italic>is associated with a more robust signaling than homodimerization [<xref ref-type="bibr" rid="B2">2</xref>]. Several studies showed that gain-of-function somatic mutations affecting the catalytic domain (specifically the ATP binding site, exons 18&#x02013;21) of <italic>EGFR </italic>in non-small cell lung carcinomas were strongly associated with response to gefitinib and erlotinib, both related <italic>EGFR</italic>-tyrosine kinase inhibitors (TKI) [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. More recently, a number of studies reported the presence of <italic>ERBB2 </italic>mutations located in the kinase domain (exons 19 and 20) in non-small cell lung carcinomas (NSCLC) that could potentially result in the activation of the tyrosine kinase activity of the receptor protein [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. In addition to NSCLC, mutations in the <italic>ERBB2 </italic>kinase domain were described in gastric, colorectal, and breast cancers [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. In our study, we sought to determine if similar respective gain-of-function <italic>EGFR </italic>and <italic>ERBB2 </italic>mutations were present in hepatoma and biliary cancers to determine the potential for <italic>ERBB </italic>-targeted therapy.</p><p>Hepatoma is the most common malignant tumor of the liver with a clear rising incidence in the number of cases in the United States, and is largely attributed to the increase in hepatitis C related liver disease [<xref ref-type="bibr" rid="B12">12</xref>]. Cancers of the biliary tract are the second most common primary hepatobiliary cancer [<xref ref-type="bibr" rid="B13">13</xref>]. There is no satisfactory treatment available for patients with hepatobiliary cancers and chemotherapy has been extremely disappointing.</p><p>The poor prognosis of patients with hepatoma and biliary cancers in addition to the lack of satisfactory therapy for advanced cases indicates a need for more effective therapeutic options. <italic>EGFR </italic>signaling is implicated in both hepatic and biliary carcinogenesis. Studies indicate that <italic>EGFR </italic>is expressed in up to 85% and 80% of hepatoma and biliary cancers, respectively [<xref ref-type="bibr" rid="B14">14</xref>], and EGF might be required for the growth of those cells [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. <italic>ERBB2 </italic>is also expressed in a significant number of hepatoma and biliary cancers acting as an independent prognostic factor and a major contributor to carcinogenesis [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. Recently, a multi-center phase 2 study looked at the efficacy and tolerability of erlotinib in advanced hepatoma and biliary cancers with encouraging results [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. In hepatoma, the reported PFS at 6 months of 32% with disease control (PR + SD) of 59% for a median duration of 4 months. The median overall survival (OS) was 13 months. In biliary cancers, the reported PFS at 6 months was 25% with disease control (PR + SD) of 55% for a median duration of 5.4 months. The median OS was 9 months.</p></sec><sec sec-type="methods"><title>Methods</title><p>In our study, we extracted genomic DNA from 40 hepatoma (18) and biliary cancers (22) samples, and 44 adenocarcinoma of the lung, the latter as a positive control for mutation detection. All hepatobiliary samples were paraffin-embedded while all lung samples were frozen. Hepatoma and biliary cancers were subjected to laser capture microdissection as previously described (Kurose K et al. Hum Mol Genet 2001) to enrich the neoplastic component. We subjected those samples to PCR-based semi-automated double stranded nucleotide sequencing, per routine of the Eng lab [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Exons 18&#x02013;21 (exon-intron junctions and flanking intronic regions) of <italic>EGFR </italic>were amplified using the primers and conditions described by Lynch et al [<xref ref-type="bibr" rid="B3">3</xref>] and those of <italic>ERBB2 </italic>were amplified using the primers and conditions described by Stephens et al [<xref ref-type="bibr" rid="B6">6</xref>]. Double stranded sequencing was performed with the ABI-3700. Mutations or variants were confirmed in both directions as well as confirmed by a second independent PCR reaction. All samples were tested against matched germline DNA derived from the related normal organ. Our samples were acquired on anonymised archived materials without personal identifiers, on an exempt protocol approved by the Ohio State University Institutional Review Board.</p></sec><sec><title>Results</title><p>All hepatoma and biliary cancers samples were negative for gain-of-function somatic mutations affecting the catalytic domain of the <italic>EGFR </italic>gene. Power calculations suggest that our negative results predict that no more than 3% of hepatoma or biliary cancers would eventually be found to carry such mutations. As a positive control for mutation detection, we sequenced <italic>EGFR </italic>exons 18&#x02013;21 in 44 adenocarcinoma of the lung and found 2 (5%) with somatic delE746-A750 mutations, previously reported to be associated with gefitinib responsiveness. In contrast, 2 (11%) of the 18 hepatoma had a single novel somatic H878Y (CAT to TAT; c.2632C &#x0003e; T) mutation in exon 21 of <italic>ERBB2 </italic>(figure <xref ref-type="fig" rid="F1">1</xref>), while none of the biliary cancers were found to have somatic mutations. None of the matched normal tissue was found to have somatic mutations for <italic>EGFR </italic>or <italic>ERBB2 </italic>found in the tumors. These are different from the reported mutations in non-small cell lung carcinomas. The H878Y missense mutation occurring in the activation domain of <italic>ERBB2 </italic>alters a basic hydrophilic residue to an acidic hydrophilic residue, and so is predicted to affect function.</p></sec><sec><title>Discussions and Conclusion</title><p>The lack of effective treatment for hepatobiliary tumors indicates a need for more effective therapeutic options. Emerging targeted therapies including EGFR inhibitors are offering promise in a variety of malignancies including hepatobiliary tumors. From this study, we conclude that gain-of-function somatic mutations affecting the catalytic domain of <italic>EGFR </italic>as described in non-small cell lung carcinomas have a predicted low yield in hepatoma and biliary cancers. A recently published study showed the lack of somatic mutations in EGFR tyrosine kinase domain in 100 hepatocellular carcinomas confirming our findings [<xref ref-type="bibr" rid="B26">26</xref>]. In contrast, we showed that 11% of hepatocellular carcinomas tested have an <italic>ERBB2 </italic>mutation occurring in the activation domain. None were found in biliary cancer specimens. Given the availability of agents interfering with <italic>ERBB2 </italic>signaling and the established role of <italic>ERBB2 </italic>in the <italic>EGFR </italic>signaling pathway, we speculate that these newly described mutations may play a role in predicting response to EGFR-targeted therapy in hepatoma in predicting response to agents that target <italic>ERBB2 </italic>and/or <italic>EGFR </italic>in hepatoma. Interestingly, one such agent, lapatinib (a dual <italic>EGFR</italic>/<italic>ERBB2 </italic>TKI), was recently reported to have activity in hepatomas (TGCR = 40%) but not in biliary cancers (TGCR = 26%) [<xref ref-type="bibr" rid="B27">27</xref>]. Cohen et al showed that in head and neck cancers although responses to gefitinib or erlotinib were not linked to kinase mutations of <italic>EGFR</italic>, one single response case was actually linked to a mutation in exon 20 of <italic>ERBB2 </italic>establishing the potential predictive value of such mutations on responses to agents that target <italic>ERBB2 </italic>and/or <italic>EGFR </italic>[<xref ref-type="bibr" rid="B28">28</xref>]. In conclusion, our findings suggest that mutations in the tyrosine kinase domain of <italic>ERBB2 </italic>in hepatoma may underlie responsiveness to agents that target <italic>ERBB2 </italic>and/or <italic>EGFR</italic>. This should trigger similar analysis as part of correlative studies in prospective studies.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>TBS conceived the study in collaboration with CE, was involved in the coordination of the study and drafted the manuscript. NW carried out the technical aspects of the mutation analysis of EGFR/ERBB2. CP made substantial contributions to conception and design and interpretation of data. MVC participated in the design of the study and was involved in revising the manuscript for intellectual content. CE conceived the study in collaboration with TBS, supervised the conduct of the study and helped draft the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/278/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>CE is a recipient of the Doris Duke Distinguished Clinical Scientist Award and is a National Scholar of the Dorothy M. Davis Heart and Lung Research Institute of The Ohio State University.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mendelsohn</surname><given-names>J</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name></person-group><article-title>Status of epidermal growth factor antagonists in the biology and treatment of cancer</article-title><source>J Clin Oncol</source><year>2003</year><volume>27</volume><fpage>2787</fpage><lpage>2799</lpage><pub-id pub-id-type="pmid">12860957</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2003.01.504</pub-id></citation></ref><ref id="B2"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Lillemoe</surname><given-names>KD</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Kelsen KP, Daly JM, Kern SE, Levin B, Tepper JE</surname></name></person-group><article-title>Cancers of the Biliary Tree: Clinical Management</article-title><source>Gastrointestinal Oncology, Principles and Practice</source><year>2002</year><edition>1</edition><publisher-name>Philadelphia. Lippincott Willaims and Wilkins</publisher-name><fpage>645</fpage><lpage>662</lpage></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Sordella</surname><given-names>R</given-names></name><name><surname>Gurubhagavatula</surname><given-names>S</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name><name><surname>Brannigan</surname><given-names>BW</given-names></name><name><surname>Harris</surname><given-names>PL</given-names></name><name><surname>Haserlat</surname><given-names>SM</given-names></name><name><surname>Supko</surname><given-names>JG</given-names></name><name><surname>Haluska</surname><given-names>FG</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Christiani</surname><given-names>DC</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name></person-group><article-title>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</article-title><source>N Engl J Med</source><volume>350</volume><fpage>2129</fpage><lpage>39</lpage><comment>2004 May 20</comment><pub-id pub-id-type="pmid">15118073</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa040938</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paez</surname><given-names>JG</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Tracy</surname><given-names>S</given-names></name><name><surname>Greulich</surname><given-names>H</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Herman</surname><given-names>P</given-names></name><name><surname>Kaye</surname><given-names>FJ</given-names></name><name><surname>Lindeman</surname><given-names>N</given-names></name><name><surname>Boggon</surname><given-names>TJ</given-names></name><name><surname>Naoki</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Eck</surname><given-names>MJ</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><article-title>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</article-title><source>Science</source><volume>304</volume><fpage>1497</fpage><lpage>500</lpage><comment>2004 Jun 4</comment><pub-id pub-id-type="pmid">15118125</pub-id><pub-id pub-id-type="doi">10.1126/science.1099314</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name><name><surname>Zakowski</surname><given-names>M</given-names></name><name><surname>Doherty</surname><given-names>J</given-names></name><name><surname>Politi</surname><given-names>K</given-names></name><name><surname>Sarkaria</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Heelan</surname><given-names>R</given-names></name><name><surname>Rusch</surname><given-names>V</given-names></name><name><surname>Fulton</surname><given-names>L</given-names></name><name><surname>Mardis</surname><given-names>E</given-names></name><name><surname>Kupfer</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Kris</surname><given-names>M</given-names></name><name><surname>Varmus</surname><given-names>H</given-names></name></person-group><article-title>EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</article-title><source>Proc Natl Acad Sci USA</source><volume>101</volume><fpage>13306</fpage><lpage>11</lpage><comment>2004 Sep 7</comment><pub-id pub-id-type="pmid">15329413</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0405220101</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Hunter</surname><given-names>C</given-names></name><name><surname>Bignell</surname><given-names>G</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>O'Meara</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Barthorpe</surname><given-names>A</given-names></name><name><surname>Blow</surname><given-names>M</given-names></name><name><surname>Brackenbury</surname><given-names>L</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Clarke</surname><given-names>O</given-names></name><name><surname>Cole</surname><given-names>J</given-names></name><name><surname>Dicks</surname><given-names>E</given-names></name><name><surname>Dike</surname><given-names>A</given-names></name><name><surname>Drozd</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>K</given-names></name><name><surname>Forbes</surname><given-names>S</given-names></name><name><surname>Foster</surname><given-names>R</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Greenman</surname><given-names>C</given-names></name><name><surname>Halliday</surname><given-names>K</given-names></name><name><surname>Hills</surname><given-names>K</given-names></name><name><surname>Kosmidou</surname><given-names>V</given-names></name><name><surname>Lugg</surname><given-names>R</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Perry</surname><given-names>J</given-names></name><name><surname>Petty</surname><given-names>R</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Ratford</surname><given-names>L</given-names></name><name><surname>Shepherd</surname><given-names>R</given-names></name><name><surname>Small</surname><given-names>A</given-names></name><name><surname>Stephens</surname><given-names>Y</given-names></name><name><surname>Tofts</surname><given-names>C</given-names></name><name><surname>Varian</surname><given-names>J</given-names></name><name><surname>West</surname><given-names>S</given-names></name><name><surname>Widaa</surname><given-names>S</given-names></name><name><surname>Yates</surname><given-names>A</given-names></name><name><surname>Brasseur</surname><given-names>F</given-names></name><name><surname>Cooper</surname><given-names>CS</given-names></name><name><surname>Flanagan</surname><given-names>AM</given-names></name><name><surname>Knowles</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Looijenga</surname><given-names>LH</given-names></name><name><surname>Malkowicz</surname><given-names>B</given-names></name><name><surname>Pierotti</surname><given-names>MA</given-names></name><name><surname>Teh</surname><given-names>B</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Harris</surname><given-names>G</given-names></name><name><surname>Goldstraw</surname><given-names>P</given-names></name><name><surname>Nicholson</surname><given-names>AG</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><article-title>Lung cancer: intragenic ERBB2 kinase mutations in tumours</article-title><source>Nature</source><volume>431</volume><fpage>525</fpage><lpage>6</lpage><comment>2004 Sep 30</comment><pub-id pub-id-type="pmid">15457249</pub-id><pub-id pub-id-type="doi">10.1038/431525b</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Serag</surname><given-names>HB</given-names></name><name><surname>Mason</surname><given-names>AC</given-names></name></person-group><article-title>Rising incidence of hepatocellular carcinoma in the United States</article-title><source>N Eng J Med</source><year>1999</year><volume>340</volume><fpage>745</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1056/NEJM199903113401001</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roskoski</surname><given-names>R</given-names><suffix>Jr</suffix></name></person-group><article-title>The ErbB/HER receptor protein-tyrosine kinases and cancer</article-title><source>Biochem Biophys Res Commun</source><volume>319</volume><fpage>1</fpage><lpage>11</lpage><comment>2004 Jun 18</comment><pub-id pub-id-type="pmid">15158434</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.04.150</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altimari</surname><given-names>A</given-names></name><name><surname>Fiorentino</surname><given-names>M</given-names></name><name><surname>Gabusi</surname><given-names>E</given-names></name><name><surname>Gruppioni</surname><given-names>E</given-names></name><name><surname>Corti</surname><given-names>B</given-names></name><name><surname>D'Errico</surname><given-names>A</given-names></name><name><surname>Grigioni</surname><given-names>WF</given-names></name></person-group><article-title>Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours</article-title><source>Dig Liver Dis</source><year>2003</year><volume>35</volume><fpage>332</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12846405</pub-id><pub-id pub-id-type="doi">10.1016/S1590-8658(03)00077-X</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>T</given-names></name><name><surname>Sakon</surname><given-names>M</given-names></name><name><surname>Tsujimoto</surname><given-names>M</given-names></name><name><surname>Higashiyama</surname><given-names>S</given-names></name><name><surname>Noda</surname><given-names>K</given-names></name><name><surname>Miyoshi</surname><given-names>E</given-names></name><name><surname>Monden</surname><given-names>M</given-names></name><name><surname>Matsuura</surname><given-names>N</given-names></name></person-group><article-title>Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma</article-title><source>Br J Cancer</source><volume>84</volume><fpage>1377</fpage><lpage>83</lpage><comment>2001 May 18</comment><pub-id pub-id-type="pmid">11355950</pub-id><pub-id pub-id-type="doi">10.1054/bjoc.2000.1580</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Sakon</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Ishiguro</surname><given-names>S</given-names></name><name><surname>Imaoka</surname><given-names>S</given-names></name><name><surname>Tsujimoto</surname><given-names>M</given-names></name><name><surname>Higashiyama</surname><given-names>S</given-names></name><name><surname>Monden</surname><given-names>M</given-names></name><name><surname>Matsuura</surname><given-names>N</given-names></name></person-group><article-title>Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma</article-title><source>Pathol Res Pract</source><year>2001</year><volume>197</volume><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">11261824</pub-id><pub-id pub-id-type="doi">10.1078/0344-0338-00016</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>BJ</given-names></name><name><surname>Huang</surname><given-names>TJ</given-names></name><name><surname>Liang</surname><given-names>QW</given-names></name><name><surname>Huang</surname><given-names>CW</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name></person-group><article-title>Quantitative detection of HER-2 oncogene amplification in primary hepatocellular carcinoma using dual FISH technique and its clinical significance</article-title><source>Yi Chuan Xue Bao</source><year>2001</year><volume>28</volume><fpage>793</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">11582736</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Expression of c-erbB-2 protein and EGF receptor in hepatitis B, cirrhosis and hepatocellular carcinoma</article-title><source>Zhonghua Bing Li Xue Za Zhi</source><year>1995</year><volume>24</volume><fpage>93</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7788735</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>NH</given-names></name><name><surname>Huang</surname><given-names>SM</given-names></name><name><surname>Chan</surname><given-names>SH</given-names></name><name><surname>Mo</surname><given-names>LR</given-names></name><name><surname>Hwang</surname><given-names>MH</given-names></name><name><surname>Su</surname><given-names>WC</given-names></name></person-group><article-title>Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract</article-title><source>Anticancer Res</source><year>1995</year><volume>15</volume><fpage>1055</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7645925</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Sakon</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Ishiguro</surname><given-names>S</given-names></name><name><surname>Imaoka</surname><given-names>S</given-names></name><name><surname>Tsujimoto</surname><given-names>M</given-names></name><name><surname>Higashiyama</surname><given-names>S</given-names></name><name><surname>Monden</surname><given-names>M</given-names></name><name><surname>Matsuura</surname><given-names>N</given-names></name></person-group><article-title>Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma</article-title><source>Pathol Res Pract</source><year>2001</year><volume>197</volume><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">11261824</pub-id><pub-id pub-id-type="doi">10.1078/0344-0338-00016</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ukita</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Terada</surname><given-names>T</given-names></name></person-group><article-title>Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry</article-title><source>J Hepatol</source><year>2002</year><volume>36</volume><fpage>780</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12044528</pub-id><pub-id pub-id-type="doi">10.1016/S0168-8278(02)00057-0</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname><given-names>PA</given-names></name><name><surname>Mahoney</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Pitot</surname><given-names>H</given-names></name><name><surname>Donehower</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>G</given-names></name><name><surname>Picus</surname><given-names>J</given-names></name><name><surname>Fitch</surname><given-names>T</given-names></name><name><surname>Geyer</surname><given-names>S</given-names></name><name><surname>Erlichman</surname><given-names>C</given-names></name></person-group><article-title>Phase II Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer</article-title><source>Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)</source><year>2004</year><volume>22</volume><fpage>4025</fpage></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname><given-names>PA</given-names></name><name><surname>Mahoney</surname><given-names>MR</given-names></name><name><surname>Allmer</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>G</given-names></name><name><surname>Donehower</surname><given-names>RC</given-names></name><name><surname>Fitch</surname><given-names>T</given-names></name><name><surname>Picus</surname><given-names>J</given-names></name><name><surname>Erlichman</surname><given-names>C</given-names></name></person-group><article-title>Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer</article-title><source>J Clin Oncol</source><volume>23</volume><fpage>6657</fpage><lpage>63</lpage><comment>2005 Sep 20</comment><pub-id pub-id-type="pmid">16170173</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.14.696</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mutter</surname><given-names>GL</given-names></name><name><surname>Lin</surname><given-names>MC</given-names></name><name><surname>Fitzgerald</surname><given-names>JT</given-names></name><name><surname>Kum</surname><given-names>JB</given-names></name><name><surname>Baak</surname><given-names>JP</given-names></name><name><surname>Lees</surname><given-names>JA</given-names></name><name><surname>Weng</surname><given-names>LP</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group><article-title>Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers</article-title><source>J Natl Cancer Inst</source><volume>92</volume><fpage>924</fpage><lpage>30</lpage><comment>2000 Jun 7</comment><pub-id pub-id-type="pmid">10841828</pub-id><pub-id pub-id-type="doi">10.1093/jnci/92.11.924</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurose</surname><given-names>K</given-names></name><name><surname>Gilley</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Watson</surname><given-names>PH</given-names></name><name><surname>Zhou</surname><given-names>XP</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group><article-title>Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas</article-title><source>Nat Genet</source><year>2002</year><volume>32</volume><fpage>355</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12379854</pub-id><pub-id pub-id-type="doi">10.1038/ng1013</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ukita</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Terada</surname><given-names>T</given-names></name></person-group><article-title>Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry</article-title><source>J Hepatol</source><year>2002</year><volume>36</volume><fpage>780</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12044528</pub-id><pub-id pub-id-type="doi">10.1016/S0168-8278(02)00057-0</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname><given-names>PA</given-names></name><name><surname>Mahoney</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Pitot</surname><given-names>H</given-names></name><name><surname>Donehower</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>G</given-names></name><name><surname>Picus</surname><given-names>J</given-names></name><name><surname>Fitch</surname><given-names>T</given-names></name><name><surname>Geyer</surname><given-names>S</given-names></name><name><surname>Erlichman</surname><given-names>C</given-names></name></person-group><article-title>Phase II Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer</article-title><source>Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)</source><year>2004</year><volume>22</volume><fpage>4025</fpage></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname><given-names>PA</given-names></name><name><surname>Mahoney</surname><given-names>MR</given-names></name><name><surname>Allmer</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>G</given-names></name><name><surname>Donehower</surname><given-names>RC</given-names></name><name><surname>Fitch</surname><given-names>T</given-names></name><name><surname>Picus</surname><given-names>J</given-names></name><name><surname>Erlichman</surname><given-names>C</given-names></name></person-group><article-title>Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer</article-title><source>J Clin Oncol</source><volume>23</volume><fpage>6657</fpage><lpage>63</lpage><comment>2005 Sep 20</comment><pub-id pub-id-type="pmid">16170173</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.14.696</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mutter</surname><given-names>GL</given-names></name><name><surname>Lin</surname><given-names>MC</given-names></name><name><surname>Fitzgerald</surname><given-names>JT</given-names></name><name><surname>Kum</surname><given-names>JB</given-names></name><name><surname>Baak</surname><given-names>JP</given-names></name><name><surname>Lees</surname><given-names>JA</given-names></name><name><surname>Weng</surname><given-names>LP</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group><article-title>Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers</article-title><source>J Natl Cancer Inst</source><volume>92</volume><fpage>924</fpage><lpage>30</lpage><comment>2000 Jun 7</comment><pub-id pub-id-type="pmid">10841828</pub-id><pub-id pub-id-type="doi">10.1093/jnci/92.11.924</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurose</surname><given-names>K</given-names></name><name><surname>Gilley</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Watson</surname><given-names>PH</given-names></name><name><surname>Zhou</surname><given-names>XP</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group><article-title>Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas</article-title><source>Nat Genet</source><year>2002</year><volume>32</volume><fpage>355</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12379854</pub-id><pub-id pub-id-type="doi">10.1038/ng1013</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>EE</given-names></name><name><surname>Lingen</surname><given-names>MW</given-names></name><name><surname>Martin</surname><given-names>LE</given-names></name><name><surname>Harris</surname><given-names>PL</given-names></name><name><surname>Branningan</surname><given-names>BW</given-names></name><name><surname>Haserlat</surname><given-names>SM</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name><name><surname>Sgroi</surname><given-names>DC</given-names></name><name><surname>Dahiya</surname><given-names>S</given-names></name><name><surname>Muir</surname><given-names>B</given-names></name><name><surname>Clark</surname><given-names>JR</given-names></name><name><surname>Rocco</surname><given-names>JW</given-names></name><name><surname>Vokes</surname><given-names>EV</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name></person-group><article-title>Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May be Linked to Mutation of ERBB2 rather than EGFR</article-title><source>Clin Cancer Res</source><volume>11</volume><fpage>8105</fpage><lpage>8</lpage><comment>2005 Nov 15</comment><pub-id pub-id-type="pmid">16299242</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0926</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramanathan</surname><given-names>RK</given-names></name><name><surname>Belani</surname><given-names>CP</given-names></name><name><surname>Singh</surname><given-names>DA</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name><name><surname>Yen</surname><given-names>Y</given-names></name><name><surname>Kindler</surname><given-names>HL</given-names></name><name><surname>Iqbal</surname><given-names>S</given-names></name><name><surname>J</surname><given-names>J</given-names></name><name><surname>Gandara</surname><given-names>DR</given-names></name></person-group><article-title>Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial</article-title><source>Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I</source><year>2006</year><volume>24</volume><fpage>4010</fpage></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Lim</surname><given-names>SG</given-names></name><name><surname>Soo</surname><given-names>R</given-names></name><name><surname>Hsieh</surname><given-names>WS</given-names></name><name><surname>Guo</surname><given-names>JY</given-names></name><name><surname>Putti</surname><given-names>T</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name><name><surname>Soong</surname><given-names>R</given-names></name><name><surname>Goh</surname><given-names>BC</given-names></name></person-group><article-title>Lack of Somatic Mutations in EGFR Tyrosine Kinase Domain in Hepatocellular and Nasopharyngeal Carcinoma</article-title><source>Pharmacogenet Genomics</source><year>2006</year><volume>16</volume><fpage>73</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16344724</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Somatic missense mutation, H878Y, found in genomic DNA from hepatoma (top chromatogram) but not in corresponding normal tissue (bottom panel).</p></caption><graphic xlink:href="1471-2407-6-278-1"/></fig></sec></back></article> 